Tumor‐Selective Altered Glycosylation and Functional Attenuation of CD73 in Human Hepatocellular Carcinoma
Karel P. Alcedo, Andres Guerrero, Venkatesha Basrur, Dong Fu, Monea L. Richardson, Joshua S. McLane, Chih‐Chiang Tsou, Alexey I. Nesvizhskii, Theodore H. Welling, Carlito B. Lebrilla, Carol A. Otey, Hong Jin Kim, M. Bishr Omary, Natasha T. Snider – 9 August 2019 – CD73, a cell‐surface N‐linked glycoprotein that produces extracellular adenosine, is a novel target for cancer immunotherapy. Although anti‐CD73 antibodies have entered clinical development, CD73 has both protumor and antitumor functions, depending on the target cell and tumor type.